Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Double Blind, Placebo Within-Patient Controlled, Multi-Center Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of AZX100 Drug Product in Trocar Sites of Arthroscopic Shoulder Surgery Patients

NCT00811577 is registered in ClinicalTrials.gov with Capstone Therapeutics as lead sponsor.

NCT NCT00811577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00811577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Double Blind, Placebo Within-Patient Controlled, Multi-Center Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of AZX100 Drug Product in Trocar Sites of Arthroscopic Shoulder Surgery Patients
Lead sponsor
Capstone Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2009
Completion date
December 31, 2010
Enrollment
150 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

scar prevention, scar reduction